Home・Aandelen Lijst・Eli Lilly and Co.

Eli Lilly and Co.

Open

SectorGezondheidszorg

1,117 -0.12

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1103.79

Max

1134.35

Belangrijke statistieken
By Trading Economics
Inkomsten	758M 7.4B
Verkoop	507M 20B
K/W Sectorgemiddelde	42.548 64.641
EPS	8.55
Dividendrendement	0.53
Winstmarge	37.355
Werknemers	50,000
EBITDA	1.3B 9.7B

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+20.47% upside

Dividenden
By Acuity
Dividendrendement Sectorgemiddelde	0.53% 2.31%
Volgende Winsten	5 aug 2026
Volgende dividenddatum	10 sep 2026
Volgende Ex Dividend datum	14 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	282B 1.1T
Vorige openingsprijs	1117.12
Vorige sluitingsprijs	1117

Nieuwssentiment

By Acuity

52%

48%

269 / 340 Rangschikking in Healthcare

Eli Lilly and Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 20:03 UTC

News

Social Media

Event

Eli Lilly's shares are declining amid negative sentiment despite expanding access to its obesity drug retatrutide and receiving FDA designation for olomorasib.

31 jul 2026, 23:06 UTC

Eli Lilly and Co shares are higher in after-market trading, though they remain below their 20-day moving average by 2.91%. No specific news was identified.

30 jul 2026, 21:01 UTC

Eli Lilly shares are higher in after-market trading, recovering from an earlier dip. Broader market sentiment remains positive amid geopolitical tensions and inflation concerns.

29 jul 2026, 23:26 UTC

Eli Lilly and Co shares are lower in after-market hours amid unusual trading activity. Broader market volatility follows the Federal Reserve's interest rate decision.

28 jul 2026, 22:06 UTC

Eli Lilly shares are lower in after-market hours, with no specific news identified. Broader market trends may be impacting sentiment following declines in the Nikkei 225 Index.

27 jul 2026, 23:16 UTC

Eli Lilly and Co shares are lower in after-market hours, continuing a decline since Monday's close amid a broader market downturn. No specific news was identified.

24 jul 2026, 23:41 UTC

Eli Lilly and Co shares declined in after-market trading, experiencing notable fluctuations without any specific news to explain the price action.

23 jul 2026, 10:06 UTC

Social Media

Eli Lilly shares are lower in pre-market trading, nearing the $1074–$1003 support zone. Broader market declines coincide with traders awaiting the ECB's interest rate decision.

22 jul 2026, 23:16 UTC

Social Media

Eli Lilly acquires ATAI for $2.8 billion, entering the psychedelic medicine sector. Shares are higher in after-market trading following the announcement.

21 jul 2026, 20:07 UTC

Social Media

News

Eli Lilly is higher today, supported by overall market strength and plans to defend against a lawsuit from Novo Nordisk over its weight-loss drugs.

20 jul 2026, 23:16 UTC

Eli Lilly's shares are roughly flat in after-market trading, amid rising treasury yields and geopolitical tensions affecting interest-sensitive sectors like pharmaceuticals.

Peer Vergelijking

Prijswijziging

Eli Lilly and Co. Prognose

Koersdoel

By TipRanks

20.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,350.89 USD 20.47%

Hoogste 1,600 USD

Laagste 1,135 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor Eli Lilly and Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Gebaseerd op 20 analisten die aandelenratings hebben gegeven aan Eli Lilly and Co. - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

269 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.